All In Biotech

Drug Trial Radar · NCT07038096

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.

Conditions

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma

Interventions

  • ZG006Drug

    ZG006 will be administered as an intravenous (IV) infusion.

  • ZG005Drug

    ZG005 will be administered as an intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Dose-limiting Toxicity (DLT)Time frame: up to 28 days
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 2 years
  3. Objective Response Rate (ORR)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guanzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.